<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20337" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Major Neurocognitive Disorder (Dementia)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Emmady</surname>
            <given-names>Prabhu D.</given-names>
          </name>
          <aff>UNC school of Medicine, Atrium Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schoo</surname>
            <given-names>Caroline</given-names>
          </name>
          <aff>VOA PACE</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prabhu Emmady declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Caroline Schoo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20337.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Dementia describes an overall decline in memory and other cognitive skills severe enough to reduce a person's ability to perform everyday activities. The progressive and persistent deterioration of cognitive function characterizes it. Affected patients often have memory loss and a partial or significant lack of insight into their deficits. This activity reviews the evaluation and management of dementia and highlights the role of the interprofessional team in caring for patients with this condition. It also reviews risk factors, pathophysiology, and challenges in diagnosing and managing this spectrum of cognitive disorders.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess&#x000a0;risk factors associated with dementia and related conditions.</p></list-item><list-item><p>Assess&#x000a0;the evaluation required for patients presenting with cognitive decline.</p></list-item><list-item><p>Evaluate&#x000a0;the commonly available management options for patients with various cognitive decline syndromes.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination among the interprofessional team to enhance care delivery and improve outcomes for patients affected by dementia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20337&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20337">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20337.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The definition of dementia has been updated in the DSM-5 criteria. It is no longer termed Dementia but is now called&#x000a0;Major Neurocognitive Disorder (MND). However, due to the common use of the term dementia in society and medical literature, it is referred to as both Dementia and&#x000a0;MND in this topic. It is worth noting the limitations of using the term dementia, including its common association exclusively with older patients, and that it is often used synonymously with Alzheimer disease.&#x000a0;MND can affect younger individuals and does not always imply Alzheimer disease as the etiology&#x000a0;of cognitive decline. MND&#x000a0;is characterized by a significant decline in at least&#x000a0;1 of the cognition domains, including executive function, complex attention, language, learning, memory, perceptual-motor, or social cognition. The decline represents a change from a patient's prior level of cognitive ability, is persistent and progressive over time, and is not associated exclusively with an episode of delirium. In addition to the cognitive decline, there must also be a decline in the patient's ability to function and perform everyday tasks. The everyday function of a patient is often evaluated in terms of the ability to perform instrumental activities of daily living, such as managing finances or medications, or, if more severe, activities of daily living, such as grooming or feeding oneself.<xref ref-type="bibr" rid="article-20337.r1">[1]</xref>&#x000a0;It is often a progressive disorder, and individuals often do not have insight into their deficits. Currently, no cure exists for any of the causes of dementia. The prevalence of dementia is expected to continue to increase along with the increasing numbers of the aging population.&#x000a0;Currently, 47 million people in the world have dementia, and the number is expected to&#x000a0;increase to 131 million by 2050.<xref ref-type="bibr" rid="article-20337.r2">[2]</xref>&#x000a0;Alzheimer disease is the 5th leading cause of death for people over the age of 65 in the United States.<xref ref-type="bibr" rid="article-20337.r3">[3]</xref> Dementia is a significant public health burden and significantly increases the costs of care, both to the individual and society. The individual lifetime cost to care for an individual with dementia was nearly $200,000 more than an individual without dementia.<xref ref-type="bibr" rid="article-20337.r4">[4]</xref>&#x000a0;In 2010, the costs of treating dementia in the United States were projected to be about $200 billion per year in the United States and $600 billion worldwide.<xref ref-type="bibr" rid="article-20337.r5">[5]</xref></p>
      </sec>
      <sec id="article-20337.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Several conditions&#x000a0;can cause MNDs, with Alzheimer dementia being the most common&#x000a0;cause, accounting for about 70% of cases.<xref ref-type="bibr" rid="article-20337.r6">[6]</xref>&#x000a0;The DSM-5 criteria for&#x000a0;MND further delineate 13 etiological subtypes that indicate the possible etiology&#x000a0;of the disorder. These subtypes include Alzheimer disease, vascular disease, frontotemporal lobar degeneration, Lewy body disease, Parkinson disease, HIV infection, Huntington disease, prion disease, substance and or medication use, traumatic brain injury, another medical condition, multiple etiologies, and unspecified. A patient may have more than&#x000a0;1 etiology contributing to MND. For example, there may be a mixed picture of Alzheimer disease with vascular disease in the same patient. Other medical conditions that can lead to dementia include progressive supranuclear palsy, corticobasal syndrome, and, less commonly, multiple system atrophy. The etiology is further characterized by "possibly" vs. "probably," assigning the degree of certainty as to the&#x000a0;cause of the MND. It often takes time to distinguish the etiology. It can be aided by many factors, including the results of imaging studies, lab studies, genetic markers, patient comorbidities, medical and family history, and clinical findings.<xref ref-type="bibr" rid="article-20337.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20337.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Alzheimer disease is&#x000a0;the most common cause of dementia, as it&#x000a0;is responsible for 70 to 80% of all cases of dementia. It can&#x000a0;occur sporadically or be familial.<xref ref-type="bibr" rid="article-20337.r7">[7]</xref>&#x000a0;Vascular dementia accounts for&#x000a0;approximately 15% of all dementia cases. Its incidence increases with age and doubles every 5.3 years.&#x000a0;Risk factors for vascular dementia include hypercholesteremia, diabetes mellitus, hypertension, and smoking.<xref ref-type="bibr" rid="article-20337.r8">[8]</xref>&#x000a0;Lewy body dementia accounts for approximately 5% of&#x000a0;dementia cases. The epidemiological data may not be completely accurate&#x000a0;because&#x000a0;the diagnosis of Lewy boy dementia is often missed.<xref ref-type="bibr" rid="article-20337.r9">[9]</xref>&#x000a0;Parkinson disease dementia accounts for approximately 10% of cases of dementia.<xref ref-type="bibr" rid="article-20337.r9">[9]</xref>&#x000a0;Frontotemporal dementia is attributed to 25% of dementia cases in patients older than 65 years of age. It is, however, the second most common cause of dementia in patients&#x000a0;younger than 65 years. There are, however, many limitations in the epidemiological studies of frontotemporal dementia, in part due to the inherent difficulty in identifying frontotemporal&#x000a0;dementia.<xref ref-type="bibr" rid="article-20337.r10">[10]</xref>&#x000a0;Creutzfeldt-Jakob disease is rare and occurs in about&#x000a0;1 to 2 cases per million per year globally.<xref ref-type="bibr" rid="article-20337.r11">[11]</xref>&#x000a0;Mixed dementia is a condition in which patients have more than&#x000a0;1 type of dementia. In this condition, Alzheimer disease with vascular dementia is the most common coexistent dementia.<xref ref-type="bibr" rid="article-20337.r12">[12]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20337.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of MND, or dementia,&#x000a0;varies depending on the subtype. Most types, except vascular dementia, are caused by the accumulation of native proteins in the brain. Alzheimer disease&#x000a0;is characterized by widespread atrophy of the cortex and deposition of&#x000a0;amyloid plaques, and neurofibrillary tangles of hyperphosphorylated tau protein in neurons, which contribute to&#x000a0;their degeneration.<xref ref-type="bibr" rid="article-20337.r7">[7]</xref>&#x000a0;Lewy body dementia and Parkinson disease dementia are characterized by the intracellular accumulation of Lewy bodies, which are insoluble aggregates of alpha-synuclein protein in the brain.<xref ref-type="bibr" rid="article-20337.r13">[13]</xref>&#x000a0;Frontotemporal dementia is characterized by various mutations leading to the deposition of ubiquitinated TDP-43 and hyperphosphorylated tau proteins in&#x000a0;the frontal and temporal lobes, leading to dementia, early personality, behavioral changes, and aphasia depending on the subtype.<xref ref-type="bibr" rid="article-20337.r10">[10]</xref>&#x000a0;Huntington disease is caused by an autosomal dominant inherited gene mutation.</p>
        <p><xref ref-type="bibr" rid="article-20337.r14">[14]</xref>&#x000a0;Prion-related dementias are caused by misfolded prions, which are proteinaceous particles that are infectious in nature and self-spreading. Prion dementias include Creutzfeldt-Jakob disease and kuru, among other syndromes.<xref ref-type="bibr" rid="article-20337.r15">[15]</xref>&#x000a0;HIV infection is associated with the development of neurocognitive disorders, in part due to the activation of macrophages and toxic inflammation leading to neurodegeneration in the brain.<xref ref-type="bibr" rid="article-20337.r16">[16]</xref>&#x000a0;Alcohol consumption, particularly high doses, and prolonged use are associated with multiple cytotoxic processes within the brain.<xref ref-type="bibr" rid="article-20337.r17">[17]</xref>&#x000a0;Vascular dementia is caused by ischemic injury to the brain (eg, stroke), leading to permanent neuronal death.<xref ref-type="bibr" rid="article-20337.r18">[18]</xref></p>
      </sec>
      <sec id="article-20337.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The pathological changes in the brain of patients with&#x000a0;different types of dementia can be varied. However, there is often overlap and mixed presentations and findings.&#x000a0;Neurodegeneration and vascular changes are seen in the brains of patients with vascular dementia. The findings can vary and&#x000a0;are related to the underlying etiology of vascular compromise, including lacunar infarcts, hemorrhagic lesions, and microvascular disease.<xref ref-type="bibr" rid="article-20337.r19">[19]</xref>&#x000a0;There is considerable overlap of neuropathological findings between dementia with Lewy body and Parkinson disease, and some overlap with Alzheimer disease.&#x000a0;Lewy body dementia and Parkinson disease are characterized by the presence of&#x000a0;Lewy bodies throughout the neocortex, brainstem, and limbic regions of the brain. Lewy bodies are intracellular aggregates of proteins, predominantly composed of alpha-synuclein proteins, which can be highlighted by various stains depending on location within the brain.&#x000a0; There is also a loss of midbrain dopaminergic neurons and a loss of cholinergic neurons in ventral forebrain nuclei. Additionally, there are neuritic plaques made up of amyloid and neurofibrillary tangles, which can overlap findings in AD.<xref ref-type="bibr" rid="article-20337.r20">[20]</xref>&#x000a0;Alzheimer disease is characterized by neuritic plaques composed of extracellular amyloid beta protein deposition and neurofibrillary tangles composed of hyperphosphorylated tau proteins. It is also common to see signs of vascular ischemic damage and hippocampal sclerosis.<xref ref-type="bibr" rid="article-20337.r21">[21]</xref><xref ref-type="bibr" rid="article-20337.r22">[22]</xref>&#x000a0;Frontotemporal dementia is characterized by atrophy in the frontal and or temporal lobes. There is neuronal loss, microvacuolation, and loss of myelin. Degeneration is found in the cortical and basal ganglia. Four pathological subtypes are named after the proteins that make up inclusions found in the brain tissue. FTLD-tau and FTLD-TDP are the most common. FTLD-FET is less common, and FTD-UPS is quite rare.<xref ref-type="bibr" rid="article-20337.r23">[23]</xref>&#x000a0;Cruetzfield Jakob disease often does not need an autopsy for diagnosis; however, it shows loss of neurons, spongiform degeneration (vacuoles in the intraneuronal space), or plaques positive for PrPSc.<xref ref-type="bibr" rid="article-20337.r24">[24]</xref></p>
      </sec>
      <sec id="article-20337.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>History must be obtained from the patient&#x000a0;and their close friends, family members, or caregivers.&#x000a0;Patients may present with symptoms of changes in behavior, getting lost in familiar neighborhoods, memory loss, mood changes, aggression, social withdrawal, self-neglect, cognitive difficulty, personality changes, difficulty performing tasks, forgetfulness, difficulty in communication, loss of independence, etc. A detailed history&#x000a0;should include past medical, family, medication, and&#x000a0;substance use history and defining observed symptoms of cognitive decline. Often, patients report different awareness of the deficits than caregivers or companions. In addition to further characterization of&#x000a0;the cognitive changes, it is important to evaluate their current functional abilities and any changes in their ability to perform daily tasks. Evaluating any safety concerns arising from the cognitive changes is also vitally important. For example, is the patient still driving and doing so safely? Have there been any episodes of wandering or getting lost? Could they get out safely if there was a fire in the house?&#x000a0;Can they still use the telephone? Are they vulnerable to financial or physical abuse? Are there firearms in the home to which they have access?&#x000a0;</p>
        <p>In addition to symptoms of dementia, the following atypical symptoms may be seen in the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>In patients with Lewy body dementia, symptoms of well-formed visual hallucinations, REM sleep behavior disorder, typical parkinsonian symptoms, and fluctuating cognition, attention, and alertness.<xref ref-type="bibr" rid="article-20337.r20">[20]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In patients with frontotemporal dementia, behavior changes, including disinhibition and apathy, and speech difficulties may be seen.<xref ref-type="bibr" rid="article-20337.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>In patients with Creutzfeld-Jakob disease, myoclonus symptoms, visual changes, ataxia, and memory and behavior changes are seen.<xref ref-type="bibr" rid="article-20337.r26">[26]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In patients with Huntington disease, symptoms of chorea, irritability, and depression can be present.<xref ref-type="bibr" rid="article-20337.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>In patients with vascular dementia, deficits can occur in stepwise declines.<xref ref-type="bibr" rid="article-20337.r27">[27]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In patients with Parkinson disease dementia, symptoms of parkinsonism characterized by bradykinesia, resting tremor, and muscle rigidity are found.&#x000a0;In addition, visual hallucinations and delusions may also be seen, especially in the late stages.<xref ref-type="bibr" rid="article-20337.r20">[20]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Patients with atypical parkinsonian syndromes also bear mentioning. Multiple system atrophy, progressive supranuclear palsy, and&#x000a0;corticobasal syndrome have symptoms of parkinsonism in addition to other characteristic findings. Multiple system atrophy&#x000a0;has symptoms of autonomic failure and cerebellar ataxia. Progressive supranuclear palsy has symptoms of frequent falls (often backward) and vertical supranuclear gaze palsy. Corticobasal syndrome has&#x000a0;progressive asymmetric muscle rigidity and alien limb phenomenon.<xref ref-type="bibr" rid="article-20337.r28">[28]</xref>&#x000a0;The physical exam should be comprehensive, including a complete neurological exam including&#x000a0;gait analysis.&#x000a0;</p>
      </sec>
      <sec id="article-20337.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The definitive diagnosis of the type of dementia can only be made at autopsy. A probable diagnosis can often be made&#x000a0;using&#x000a0;clinical history predominantly, sometimes aided by brain imaging and additional&#x000a0;laboratory&#x000a0;evaluation. Excluding treatable causes of cognitive impairment is also important in the initial evaluation.&#x000a0;All&#x000a0;domains of cognition must be assessed. There are multiple cognitive evaluation tools available for use in a clinical setting, including the Mini-mental status examination, Montreal Cognitive Assessment, Saint Louis University Mental Status, Addenbrooke's Cognitive Examination&#x02013;Revised, the modified mini-mental state examination, Mini-Cog, and Rowland Universal Dementia Assessment Scale.&#x000a0; See <bold>Table.</bold>&#x000a0;Pain Assessment in Advanced Dementia Scale.</p>
        <p>Each tool has different advantages; for example, the&#x000a0;Montreal cognitive assessment takes approximately 10 minutes and is better suited&#x000a0;for detecting&#x000a0;mild cognitive impairment besides MND. In contrast,&#x000a0;the Mini-Cog&#x000a0;takes approximately 3 minutes to administer and is predominantly used to screen for MND. The Rowland Universal Dementia Assessment Scale is often used for cross-cultural evaluations and can be administered with&#x000a0;an interpreter. None of these cognitive evaluations alone can diagnose MND, as a decline in function of daily tasks is also needed to meet the diagnostic criteria. These studies can be repeated over time to document the progression of decline. They can give an idea of the severity of the deficit along with specific cognitive domains that are affected. Specialized, more in-depth neuropsychological testing can&#x000a0;provide further diagnostic information and help differentiate subtle differences or hard-to-diagnose cases. Laboratory tests to check in all&#x000a0;patients during the evaluation of dementia include complete blood count, urinalysis, metabolic panel, Vitamin B12, folic acid, thyroid function tests, and serological tests for syphilis and HIV. Under certain circumstances, checking erythrocyte sedimentation rate, lumbar puncture, heavy metal screen, ceruloplasmin levels, Lyme disease titer, or serum protein electrophoresis may be appropriate.&#x000a0;</p>
        <p>Brain imaging is sometimes ordered, particularly if the age of onset is relatively early, atypical or rapidly progressing symptoms are present, or there is diagnostic uncertainty. A brain MRI without contrast is often the initial test ordered. It is&#x000a0;valuable for evaluating signs of vascular or ischemic disease and localized regions or global atrophy that may be seen.&#x000a0;A DaTscan uses a radiotracer to highlight dopamine transporter proteins in a SPECT scan on the presynaptic dopaminergic neurons. This scan can aid in differentiating pathologies that involve loss of the striatal dopaminergic pathway, including Parkinson disease, multiple system atrophy, progressive nuclear palsy, cortical-basal degeneration, and Lewy body dementia from other syndromes.<xref ref-type="bibr" rid="article-20337.r29">[29]</xref>&#x000a0;Often reserved for academic settings, functional brain imaging with PET, SPECT, and fMRI&#x000a0;can help in the early diagnosis and monitoring of patients with dementia, especially&#x000a0;AD. These can also help differentiate the etiology of dementia. These are expensive, and&#x000a0;routine use in clinical practice is not indicated.<xref ref-type="bibr" rid="article-20337.r30">[30]</xref>&#x000a0;There are new CSF and blood tests under research to help identify Alzheimer disease and evaluate concentrations of amyloid and phosphorylated tau proteins as well as markers of neurodegeneration, including neurofilament light chain and glial fibrillar acidic proteins. These tests are not yet ready for regular clinical use.<xref ref-type="bibr" rid="article-20337.r31">[31]</xref></p>
      </sec>
      <sec id="article-20337.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>FDA-approved medications to improve cognitive function include cholinesterase inhibitors and memantine. Cholinesterase inhibitors include&#x000a0;donepezil, galantamine, and rivastigmine. Cholinesterase inhibitors prevent the breakdown of acetylcholine and aim to&#x000a0;slow or delay the worsening of symptoms. Memantine is an NMDA antagonist and decreases the activity of glutamine. Donepezil is approved for all stages of Alzheimer disease, rivastigmine is approved for all stages of Alzheimer disease in its patch form, and mild to moderate stages with oral formulations. Galantamine is approved for mild to moderate stages and memantine for moderate to severe stages.<xref ref-type="bibr" rid="article-20337.r32">[32]</xref>&#x000a0;Acetylcholinesterase inhibitors lead to&#x000a0;a variable response among patients, with not all patients showing benefit. There are possible contraindications to their use and significant side effects, including the potential for&#x000a0;cardiovascular complications, peptic ulcer disease, and weight loss.&#x000a0;Memantine may have neuroprotective benefits as it serves as an uncompetitive NMDA receptor antagonist and can prevent neurotoxic and excessive calcium influx to the neuron.<xref ref-type="bibr" rid="article-20337.r33">[33]</xref>&#x000a0;The benefits seen with the use of both acetylcholinesterase inhibitors and memantine are often modest, and many patients and providers choose to forgo pharmacologic treatment.&#x000a0;</p>
        <p>Aducanumab is a recombinant monoclonal antibody directed against amyloid beta that was recently approved by the FDA for the treatment of mild Alzheimer disease. Its approval remains highly controversial. The drug is costly and does not have clear, proven clinical benefits. It was approved based on positive clinical results seen in only&#x000a0;1 of the&#x000a0;2 phase III trials and aducanumab's effect on a surrogate endpoint (reducing amyloid beta plaques in the brain), which has not been proven clinically significant.<xref ref-type="bibr" rid="article-20337.r34">[34]</xref>&#x000a0;Lifestyle modifications to optimize cognitive function include optimizing sleep, eating an anti-inflammatory diet, adequate exercise, treating hearing or vision loss, minimizing stress, and maintaining normal blood sugar, cholesterol, and blood pressure levels.<xref ref-type="bibr" rid="article-20337.r35">[35]</xref>&#x000a0;Behavioral symptoms include irritability, anxiety, and depression. Antidepressants and sometimes antipsychotics can help with these symptoms. In addition, non-drug approaches like supportive care, memory training, physical exercise programs, and mental and social stimulation&#x000a0;must be employed in symptom control. Patients and their families&#x000a0;should be counseled about the disease and its consequences. They&#x000a0;should be provided with all the necessary information about what to expect and how to react. Patients and their families should&#x000a0;also be encouraged to seek&#x000a0;social service consultations and to register with support groups and societies. Coaching caregivers on skills such as redirection and reassurance as opposed to repeated correction of patients confused due to dementia can avoid or de-escalate possible behavioral symptoms.&#x000a0;Driving restrictions may have to be imposed.</p>
      </sec>
      <sec id="article-20337.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for major neurocognitive disorder (dementia) include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Delirium&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Depression&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Drug use</p>
          </list-item>
          <list-item>
            <p>Normal age-associated memory&#x000a0;changes&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Mild cognitive impairment&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Stress</p>
          </list-item>
          <list-item>
            <p>Structural brain abnormalities like subdural&#x000a0;hematoma, brain tumor, and normal pressure hydrocephalus</p>
          </list-item>
          <list-item>
            <p>Infections like HIV and neurosyphilis</p>
          </list-item>
          <list-item>
            <p>Thiamine deficiency</p>
          </list-item>
          <list-item>
            <p>Vitamin B12&#x000a0;deficiency</p>
          </list-item>
          <list-item>
            <p>Folic acid&#x000a0;deficiency&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Thyroid disorders</p>
          </list-item>
          <list-item>
            <p>Metabolic abnormalities and derangements</p>
          </list-item>
          <list-item>
            <p>Medication-induced</p>
          </list-item>
          <list-item>
            <p>Vitamin E&#x000a0;deficiency</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20337.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of dementia is poor. Dementia is often a progressive condition with no cure or treatment. The 1-year mortality rate was 30 to 40%, while the 5-year mortality rate was 60 to 65%. Men had a higher risk than women. Mortality rates among admitted patients with dementia were higher than those with cardiovascular diseases.<xref ref-type="bibr" rid="article-20337.r36">[36]</xref></p>
      </sec>
      <sec id="article-20337.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Dementia can affect many body systems and can lead to the following complications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Inadequate nutrition</p>
          </list-item>
          <list-item>
            <p>Pneumonia</p>
          </list-item>
          <list-item>
            <p>Inability to perform self-care tasks</p>
          </list-item>
          <list-item>
            <p>Personal safety challenges</p>
          </list-item>
          <list-item>
            <p>Fractures due to falls</p>
          </list-item>
          <list-item>
            <p>Hallucinations and delusions</p>
          </list-item>
          <list-item>
            <p>Apathy</p>
          </list-item>
          <list-item>
            <p>Agitation</p>
          </list-item>
          <list-item>
            <p>Dysphagia</p>
          </list-item>
          <list-item>
            <p>Death</p>
          </list-item>
          <list-item>
            <p>Depression</p>
          </list-item>
          <list-item>
            <p>Incontinence</p>
          </list-item>
          <list-item>
            <p>Personality changes</p>
          </list-item>
          <list-item>
            <p>Infections<xref ref-type="bibr" rid="article-20337.r37">[37]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20337.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The diagnosis of dementia can be&#x000a0;stressful and overwhelming for patients and their families. Patient and caregiver education&#x000a0;is vital to the clinical management of patients with dementia. Counseling must be given about regular clinic visits, medication compliance, a healthy diet, exercise, and sleep hygiene. Safety concerns become increasingly important as the disease progresses. Special attention should be paid to potential safety concerns, including when to retire from driving, the risk of wandering or getting lost, risks of fire or cooking mishaps, or lack of ability to prepare food for oneself. Patients with dementia often&#x000a0;have a lack of insight into their limitations. Caregivers do better redirecting or reassuring patients rather than trying to correct them. Support groups can help with the reduction of issues like anxiety, frustration, anger, loneliness,&#x000a0;and depression.&#x000a0;The patients and caregivers should be counseled about the diagnosis and the prognosis. Creating an individualized care plan can empower the patient.</p>
      </sec>
      <sec id="article-20337.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Dementia is a common condition, and its prevalence is expected to increase with time. Various underlying etiologies and disease states cause it, and each may present differently. An interprofessional approach is recommended when managing patients with dementia. Interventions, including&#x000a0;care coordination and interprofessional communication, can help reduce hospitalization and decrease emergency department visits.&#x000a0;Physicians must coordinate with other healthcare workers, including physicians, pharmacists, social workers, and nurses, when managing patients with dementia. Any medication change must be carefully coordinated with all physicians involved in the patient's care. Pharmacists can help with counseling about medication side effects and compliance, and attention should be paid to over-the-counter medications and supplements as much as prescribed medications. Safety&#x000a0;in the current living situation must be reviewed during every clinic visit, and social workers may&#x000a0;be consulted&#x000a0;to assess the safety and adequacy of the living situation and caregiver support. Involving family members&#x000a0;and&#x000a0;caregivers is an important aspect of the care of patients with dementia. They must be encouraged to accompany the patient during clinic visits to provide an accurate clinical history and to reiterate and enact the plan at home.&#x000a0;</p>
      </sec>
      <sec id="article-20337.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20337&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20337">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/major-neurocognitive-disorder-dementia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20337">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20337/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20337">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-20337.s16">
        <fig id="article-20337.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Pain Assessment in Advanced Dementia (PAINAD) Scale Contributed by D Schwerin, MD, FACEP, FAEMS, FAAEM</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PAINAD__Scale" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-20337.s17">
        <title>References</title>
        <ref id="article-20337.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sachdev</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Blacker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Blazer</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Ganguli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jeste</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Paulsen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Classifying neurocognitive disorders: the DSM-5 approach.</article-title>
            <source>Nat Rev Neurol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>10</volume>
            <issue>11</issue>
            <fpage>634</fpage>
            <page-range>634-42</page-range>
            <pub-id pub-id-type="pmid">25266297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arvanitakis</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Management of Dementia: Review.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>Oct</month>
            <day>22</day>
            <volume>322</volume>
            <issue>16</issue>
            <fpage>1589</fpage>
            <page-range>1589-1599</page-range>
            <pub-id pub-id-type="pmid">31638686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <article-title>2021 Alzheimer's disease facts and figures.</article-title>
            <source>Alzheimers Dement</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>327</fpage>
            <page-range>327-406</page-range>
            <pub-id pub-id-type="pmid">33756057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jutkowitz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Gaugler</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>MacLehose</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Dowd</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kuntz</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Societal and Family Lifetime Cost of Dementia: Implications for Policy.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>10</issue>
            <fpage>2169</fpage>
            <page-range>2169-2175</page-range>
            <pub-id pub-id-type="pmid">28815557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langa</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Is the risk of Alzheimer's disease and dementia declining?</article-title>
            <source>Alzheimers Res Ther</source>
            <year>2015</year>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <pub-id pub-id-type="pmid">25815064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mayeux</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.</article-title>
            <source>Biochem Pharmacol</source>
            <year>2014</year>
            <month>Apr</month>
            <day>15</day>
            <volume>88</volume>
            <issue>4</issue>
            <fpage>640</fpage>
            <page-range>640-51</page-range>
            <pub-id pub-id-type="pmid">24398425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schachter</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Alzheimer's disease.</article-title>
            <source>Dialogues Clin Neurosci</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-100</page-range>
            <pub-id pub-id-type="pmid">22034442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Brien</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Vascular dementia.</article-title>
            <source>Lancet</source>
            <year>2015</year>
            <month>Oct</month>
            <day>24</day>
            <volume>386</volume>
            <issue>10004</issue>
            <fpage>1698</fpage>
            <page-range>1698-706</page-range>
            <pub-id pub-id-type="pmid">26595643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kane</surname>
                <given-names>JPM</given-names>
              </name>
              <name>
                <surname>Surendranathan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bentley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>SAH</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Allan</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>McNally</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>McKeith</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Burn</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Clinical prevalence of Lewy body dementia.</article-title>
            <source>Alzheimers Res Ther</source>
            <year>2018</year>
            <month>Feb</month>
            <day>15</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <pub-id pub-id-type="pmid">29448953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lavakumar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tampi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Balachandran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tampi</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Frontotemporal dementia: latest evidence and clinical implications.</article-title>
            <source>Ther Adv Psychopharmacol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-48</page-range>
            <pub-id pub-id-type="pmid">29344342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uttley</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hilton</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>e2</fpage>
            <page-range>e2-e10</page-range>
            <pub-id pub-id-type="pmid">31876504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Custodio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Montesinos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lira</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Herrera-P&#x000e9;rez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bardales</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Valeriano-Lorenzo</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Mixed dementia: A review of the evidence.</article-title>
            <source>Dement Neuropsychol</source>
            <year>2017</year>
            <season>Oct-Dec</season>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>364</fpage>
            <page-range>364-370</page-range>
            <pub-id pub-id-type="pmid">29354216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKeith</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Dementia with Lewy bodies.</article-title>
            <source>Dialogues Clin Neurosci</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>333</fpage>
            <page-range>333-41</page-range>
            <pub-id pub-id-type="pmid">22033743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McColgan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tabrizi</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Huntington's disease: a clinical review.</article-title>
            <source>Eur J Neurol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-34</page-range>
            <pub-id pub-id-type="pmid">28817209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salardini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>An Overview of Primary Dementias as Clinicopathological Entities.</article-title>
            <source>Semin Neurol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-166</page-range>
            <pub-id pub-id-type="pmid">30925609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Ances</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>HIV-associated neurocognitive disorder.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>976</fpage>
            <page-range>976-86</page-range>
            <pub-id pub-id-type="pmid">24156898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gutwinski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schreiter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Priller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Henssler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wiers</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Heinz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Drink and Think: Impact of Alcohol on Cognitive Functions and Dementia - Evidence of Dose-Related Effects.</article-title>
            <source>Pharmacopsychiatry</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>136</fpage>
            <page-range>136-143</page-range>
            <pub-id pub-id-type="pmid">28950395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sanders</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Schoo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kalish</surname>
                <given-names>VB</given-names>
              </name>
            </person-group>
            <chapter-title>Vascular Dementia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">28613567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalaria</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease.</article-title>
            <source>Acta Neuropathol</source>
            <year>2016</year>
            <month>May</month>
            <volume>131</volume>
            <issue>5</issue>
            <fpage>659</fpage>
            <page-range>659-85</page-range>
            <pub-id pub-id-type="pmid">27062261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomperts</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2 Dementia</issue>
            <fpage>435</fpage>
            <page-range>435-63</page-range>
            <pub-id pub-id-type="pmid">27042903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masliah</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mallory</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Deerinck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>DeTeresa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lamont</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Terry</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Carragher</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ellisman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Re-evaluation of the structural organization of neuritic plaques in Alzheimer's disease.</article-title>
            <source>J Neuropathol Exp Neurol</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>619</fpage>
            <page-range>619-32</page-range>
            <pub-id pub-id-type="pmid">8229081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amador-Ortiz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Neuropathology of hippocampal sclerosis.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2008</year>
            <volume>89</volume>
            <fpage>569</fpage>
            <page-range>569-72</page-range>
            <pub-id pub-id-type="pmid">18631779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mackenzie</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies.</article-title>
            <source>J Neurochem</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>138 Suppl 1</volume>
            <fpage>54</fpage>
            <page-range>54-70</page-range>
            <pub-id pub-id-type="pmid">27306735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gambetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Parchi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Sporadic and familial CJD: classification and characterisation.</article-title>
            <source>Br Med Bull</source>
            <year>2003</year>
            <volume>66</volume>
            <fpage>213</fpage>
            <page-range>213-39</page-range>
            <pub-id pub-id-type="pmid">14522861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finger</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Frontotemporal Dementias.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2 Dementia</issue>
            <fpage>464</fpage>
            <page-range>464-89</page-range>
            <pub-id pub-id-type="pmid">27042904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manix</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kalakoti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thakur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Menger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guthikonda</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nanda</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy.</article-title>
            <source>Neurosurg Focus</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>E2</fpage>
            <pub-id pub-id-type="pmid">26646926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strub</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Vascular dementia.</article-title>
            <source>Ochsner J</source>
            <year>2003</year>
            <season>Winter</season>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-3</page-range>
            <pub-id pub-id-type="pmid">22470255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deutschl&#x000e4;nder</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Wszolek</surname>
                <given-names>ZK</given-names>
              </name>
            </person-group>
            <article-title>Atypical parkinsonian syndromes: a general neurologist's perspective.</article-title>
            <source>Eur J Neurol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-58</page-range>
            <pub-id pub-id-type="pmid">28803444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akdemir</surname>
                <given-names>&#x000dc;&#x000d6;</given-names>
              </name>
              <name>
                <surname>Bora Tok&#x000e7;aer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Atay</surname>
                <given-names>L&#x000d6;</given-names>
              </name>
            </person-group>
            <article-title>Dopamine transporter SPECT imaging in Parkinson&#x02019;s disease and parkinsonian disorders.</article-title>
            <source>Turk J Med Sci</source>
            <year>2021</year>
            <month>Apr</month>
            <day>30</day>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>400</fpage>
            <page-range>400-410</page-range>
            <pub-id pub-id-type="pmid">33237660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brooks</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Future Imaging in Dementia.</article-title>
            <source>Semin Nucl Med</source>
            <year>2021</year>
            <month>May</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>303</fpage>
            <page-range>303-308</page-range>
            <pub-id pub-id-type="pmid">33353722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teunissen</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Verberk</surname>
                <given-names>IMW</given-names>
              </name>
              <name>
                <surname>Thijssen</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Vermunt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hansson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Zetterberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>van der Flier</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Mielke</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Del Campo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.</article-title>
            <source>Lancet Neurol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-77</page-range>
            <pub-id pub-id-type="pmid">34838239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Briggs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kennelly</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Drug treatments in Alzheimer's disease.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-53</page-range>
            <pub-id pub-id-type="pmid">27251914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robinson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Memantine: a review of its use in Alzheimer's disease.</article-title>
            <source>Drugs</source>
            <year>2006</year>
            <volume>66</volume>
            <issue>11</issue>
            <fpage>1515</fpage>
            <page-range>1515-34</page-range>
            <pub-id pub-id-type="pmid">16906789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knopman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Perlmutter</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks.</article-title>
            <source>Neurology</source>
            <year>2021</year>
            <month>Sep</month>
            <day>14</day>
            <volume>97</volume>
            <issue>11</issue>
            <fpage>545</fpage>
            <page-range>545-547</page-range>
            <pub-id pub-id-type="pmid">34233938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dominguez</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Veronese</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vernuccio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Catanese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Inzerillo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salemi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barbagallo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Nutrition, Physical Activity, and Other Lifestyle Factors in the Prevention of Cognitive Decline and Dementia.</article-title>
            <source>Nutrients</source>
            <year>2021</year>
            <month>Nov</month>
            <day>15</day>
            <volume>13</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">34836334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van de Vorst</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Vaartjes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Geerlings</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Bots</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Koek</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Prognosis of patients with dementia: results from a prospective nationwide registry linkage study in the Netherlands.</article-title>
            <source>BMJ Open</source>
            <year>2015</year>
            <month>Oct</month>
            <day>28</day>
            <volume>5</volume>
            <issue>10</issue>
            <fpage>e008897</fpage>
            <pub-id pub-id-type="pmid">26510729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20337.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vogelgsang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wolff-Menzler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Abdel-Hamid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wiltfang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hessmann</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular and metabolic comorbidities in patients with Alzheimer's disease and vascular dementia compared to a psychiatric control cohort.</article-title>
            <source>Psychogeriatrics</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>393</fpage>
            <page-range>393-401</page-range>
            <pub-id pub-id-type="pmid">29993172</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
